[go: up one dir, main page]

AR009446A1 - Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion. - Google Patents

Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.

Info

Publication number
AR009446A1
AR009446A1 ARP970106203A ARP970106203A AR009446A1 AR 009446 A1 AR009446 A1 AR 009446A1 AR P970106203 A ARP970106203 A AR P970106203A AR P970106203 A ARP970106203 A AR P970106203A AR 009446 A1 AR009446 A1 AR 009446A1
Authority
AR
Argentina
Prior art keywords
treatment
tranilast
prevention
pharmaceutical composition
manufacture
Prior art date
Application number
ARP970106203A
Other languages
English (en)
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25101171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR009446(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of AR009446A1 publication Critical patent/AR009446A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Utilizacion del ácido 2-(3,4-dimetoxicinamoil)aminobenzoico (Tranilast) o una sal farmacéuticamente aceptable del mismo en la fabricacion de unacomposicion farmacéutica para el tratamiento o la prevencion de la restenosis asociada con intervenciones en las coronarias, siendo la duracion deltratamiento menor de 3 meses después de la intervencion en las coronarias y efectuándose el tratamiento a una dosis diaria suficiente para mantener unaconcentracion de Tranilast en el plasma en una concentracion aproximadamente 100 micrones molar; en la cual se impide la proliferacion de las células delmusculo liso vascular-humano debido a este tratamiento. También se provee una composicion farmacéutica para ser usada en dicho tratamiento yel procedimientode fabricacion de un agente para el tratamiento o la prevencion de la restenosis asociada con intervenciones en las coronarias.
ARP970106203A 1996-12-30 1997-12-29 Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion. AR009446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/774,418 US6019104A (en) 1996-12-30 1996-12-30 Method for the treatment or prevention of restenosis associated with coronary intervention

Publications (1)

Publication Number Publication Date
AR009446A1 true AR009446A1 (es) 2000-04-12

Family

ID=25101171

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970106203A AR009446A1 (es) 1996-12-30 1997-12-29 Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.

Country Status (19)

Country Link
US (1) US6019104A (es)
EP (1) EP0891185A2 (es)
KR (1) KR19990087396A (es)
CN (1) CN1220599A (es)
AR (1) AR009446A1 (es)
AU (1) AU7854198A (es)
BR (1) BR9707877A (es)
CA (1) CA2247306A1 (es)
CZ (1) CZ251198A3 (es)
EA (1) EA001931B1 (es)
HU (1) HUP9904029A3 (es)
ID (1) ID20165A (es)
IL (1) IL125660A0 (es)
NO (1) NO983947D0 (es)
NZ (1) NZ331338A (es)
PE (1) PE27399A1 (es)
TR (1) TR199801698T1 (es)
WO (1) WO1998029104A2 (es)
ZA (1) ZA9711719B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326828C (en) 1998-05-05 2008-07-22 Scimed Life Systems, Inc. Stent with smooth ends
KR20010101934A (ko) * 1999-02-03 2001-11-15 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 관상혈관 시술과 관련된 심혈관 사건의 예방 및 감소 방법
BR0007901A (pt) * 1999-02-03 2001-10-30 Smithkline Beecham Corp Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária
AU2001243248A1 (en) * 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (es) * 1973-01-18 1981-09-22
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤

Also Published As

Publication number Publication date
CA2247306A1 (en) 1998-07-09
CN1220599A (zh) 1999-06-23
WO1998029104A3 (en) 1998-10-01
ID20165A (id) 1998-10-15
BR9707877A (pt) 1999-07-27
EA001931B1 (ru) 2001-10-22
EP0891185A2 (en) 1999-01-20
PE27399A1 (es) 1999-03-31
US6019104A (en) 2000-02-01
NZ331338A (en) 2000-12-22
EA199800781A1 (ru) 1999-12-29
HUP9904029A3 (en) 2000-11-28
IL125660A0 (en) 1999-04-11
NO983947D0 (no) 1998-08-27
ZA9711719B (en) 1998-06-25
KR19990087396A (ko) 1999-12-27
HUP9904029A2 (hu) 2000-05-28
TR199801698T1 (xx) 1999-03-22
AU7854198A (en) 1998-07-31
WO1998029104A2 (en) 1998-07-09
CZ251198A3 (cs) 1999-08-11

Similar Documents

Publication Publication Date Title
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
IS1694B (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
BR9506029A (pt) Forma farmaêutica oral de múltipla dosagem unitária em tablete processo para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem para o tratamento de doenças inflamatórias gastrointestinais em maniferos e no homem e embalgem de ampola de pressão transversal
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
GR1000465B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιεχουν ακετυλ d-καρνιτινη για την θεραπευτικη αγωγη του γλαυκωματος.
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
NO934768L (no) Sammensetning av L-DOPA-estere
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
AR009446A1 (es) Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
NO982988D0 (no) Middel for profylakse og behandling av diabetiske komplikasjoner
AR039682A1 (es) Un medicamento para el tratamiento o prevencion del acne
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
SE8105500L (sv) Psykotropa lekemedel
ES2038726T3 (es) Procedimiento de preparacion de un medicamento que contiene n-alquilescopolaminio y nitroglicerina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal